Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

KPV: sourcing, documentation and price

KPV is the endogenous tripeptide Lysine-Proline-Valine, derived from α-melanocyte-stimulating hormone. This page covers its identifiers, the mechanisms studied, and what a research-supply catalogue can and cannot tell yo

peptides-pro Editorial

KPV is the tripeptide Lysine-Proline-Valine, also written Lys-Pro-Val, an endogenous fragment derived from the C-terminal region of α-melanocyte-stimulating hormone (α-MSH). It is classified as a host defense peptide / anti-inflammatory tripeptide. The evidence block does not provide a sequence string, molecular formula, molecular weight, CAS number, or purity specification for KPV; those identifiers are not stated in the supplied sources and are therefore not reported here. The work described in the evidence centres on inflammatory signalling and on ROS-dependent modulation of the AKT/mTORC1/PPARγ axis.

KPV is supplied as a research-use-only laboratory material. In the studies below, it appears either as a free tripeptide or as a component of an engineered oral-delivery conjugate. Where a finding comes from an animal model or from cultured cells, that is stated. No human dosing, human pharmacokinetic, or clinical outcome data appear in the evidence block.

Research Studies

KPV and oral peptide delivery across gastrointestinal barriers

Oral delivery of peptide therapeutics is limited by gastrointestinal degradation and poor intestinal absorption. A self-immolative peptide prodrug conjugate (SIPPC) platform was developed to address this, combining a hydrophilic polyethylene glycol segment, a reactive oxygen species (ROS)-responsive hydrophobic self-immolative module, and a hydrolyzable scaffold. The conjugates assembled spontaneously into micelle-like nanoparticles. Using three anti-inflammatory peptides — KPV, Ac-QAW, and IRW — the engineered conjugates showed gastrointestinal stability, mucus penetration, and ROS-responsive release at inflamed sites [1].

This is a formulation and delivery study. It reports on the behaviour of the conjugate platform, not on a therapeutic outcome in humans. The relevance to sourcing is that KPV has been evaluated as a cargo in an oral-delivery system, which is a different research context from the free peptide.

KPV and adipogenesis in a cell model

KPV has been recognised for anti-inflammatory and antioxidant activities, but its role in adipocyte differentiation had not been investigated. In a study using MDI-induced differentiation of a cell model, KPV was examined for regulatory effects on adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signalling [2]. The evidence block does not give the numerical results, the cell line name beyond the MDI induction context, or the concentrations tested. The finding is therefore reported as a mechanism-level observation in a cultured-cell model, not as an in vivo or human effect.

KPV and hepatic lipid accumulation in HepG2 cells

Hepatocellular steatosis, an early stage within the non-alcoholic fatty liver disease (NAFLD) spectrum, is characterised by excessive lipid accumulation and oxidative stress in hepatocytes. A study examined the protective role of KPV, described as an endogenous tripeptide derived from α-MSH, in HepG2 cells, reporting attenuation of hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway [3]. This is an in vitro hepatocyte model. No animal or human data are given in the evidence block for this endpoint.

KPV and the PPARγ pathway: what the two cell studies share

Both cell-based reports converge on PPARγ and on ROS as the signalling context in which KPV was studied — one in an adipocyte-differentiation model, one in a hepatocyte model [2][3]. The table below compares the two on the dimensions the evidence block actually states.

DimensionAdipogenesis study [2]Hepatic steatosis study [3]
ModelMDI-induced differentiation, cell modelHepG2 cells
Process examinedAdipogenesis and lipid metabolismHepatic lipid accumulation
Signalling contextROS-mediated AKT/mTORC1/PPARγROS-dependent PPARγ
Reported directionAttenuation of adipogenesisAttenuation of lipid accumulation
Species levelIn vitroIn vitro

Neither study is a clinical trial. Neither reports a human dose. The shared PPARγ theme is a mechanistic observation in cultured cells, and it should not be read as a demonstrated whole-organism effect.

KPV in the host defense peptide literature for inflammatory bowel disease

Inflammatory bowel diseases are chronic disorders affecting the gastrointestinal tract, causing inflammation and tissue damage, and current treatments often carry adverse effects. A short review of host defense peptides (HDPs) describes them as emerging candidates in this area [5]. KPV belongs to the host defense peptide class, and this review places the class in the IBD research context. The evidence block does not state that KPV itself was tested in an IBD model in this review, so no such claim is made here.

KPV and the peptide market in sport and bodybuilding

A critical review of peptide and peptide-analog drug use in recreational and professional sport and bodybuilding describes a shift from anabolic-androgenic steroids toward peptides and peptide analogues, marketed as more selective and ostensibly safer alternatives. The review names growth hormone secretagogues such as Ipamorelin among the agents discussed [4]. This is a market and regulatory commentary, not an efficacy study, and the evidence block does not report KPV-specific findings from it. It is cited here only because it documents the broader context in which research peptides are marketed.

KPV and documentation: what the evidence does and does not establish

The supplied evidence supports the following statements about KPV: it is an endogenous tripeptide derived from α-MSH [2][3]; it has been studied in cultured-cell models of adipogenesis and hepatic lipid accumulation [2][3]; it has been used as a cargo peptide in an oral-delivery conjugate platform [1]; and it belongs to the host defense peptide class discussed in the IBD literature [5].

The supplied evidence does not establish: a human dose; a human pharmacokinetic profile; a clinical endpoint; a CAS number; a molecular weight; a purity specification; or a shelf-life. Those items are absent from the evidence block and are not invented here. A buyer comparing catalogue listings should treat any such figure as coming from the supplier's own documentation, not from the sources on this page.

KPV and sourcing: what a catalogue can state

A research-supply catalogue can state the formal name, the class, the catalogue identifier, the pack size, and the price. It cannot state a therapeutic indication, a dose, or an outcome. For KPV, the formal name is Lysine-Proline-Valine, and the catalogue entry is KPV. The evidence block does not supply a price, a purity grade, or a batch specification, so none is quoted on this page.

Where a study used KPV as part of a conjugate rather than as the free peptide [1], the material in that study is not the same material as a standalone KPV vial. Researchers designing a replication should note the difference between the free tripeptide and the SIPPC conjugate format.

KPV and the limits of extrapolation from cell models

The two mechanistic reports [2][3] are in vitro. The delivery report [1] describes a formulation platform. The IBD review [5] is a class-level review. The sport review [4] is a market commentary. None of these is a human trial of KPV. Any statement that KPV produces a given effect in a person is outside what the evidence block supports, and is not made on this page.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. If you are considering a compound for yourself, speak to a licensed clinician.

Sources

WhatsApp